Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by u2bobon Jul 05, 2017 10:29am
140 Views
Post# 26434938

News

NewsDiagnos Inc (2) Symbol C : ADK Shares Issued 165,727,727 Close 2017-07-04 C$ 0.145 Recent Sedar Documents View Original Document Diagnos to open second eye screening clinic in Calif. 2017-07-05 10:09 ET - News Release Mr. Andre Larente reports DIAGNOS ANNOUNCES SUCCESSFUL PILOT AT CHAPARRAL MEDICAL GROUP IN CALIFORNIA AND A 3 YEAR CONTRACT WITH THE OPENING OF A SECOND EYE SCREENING CLINIC Diagnos Inc. has signed a three-year agreement with Chaparral Medical Group. We are also happy to announce the opening of a second eye screening clinic in California. ''The United States is a key market for Diagnos. By working closely with Chaparral`s 23 clinics, we have developed a new business model for the US market. Chaparral is a very high value referral account with the best practice in healthcare. We are very proud to be working and having them as our customer. We've learned a lot from the one year pilot program. Now is the time to build on it and increase our market share of diabetic retinopathy screening. Having a second clinic will have a significant contribution to the number of patients under the guard of CARA in the USA" said Yves-Stephane Couture, VP Sales of DIAGNOS. Yearly eye exams for diabetic patients are a common requirement guideline of almost all endocrinology society and medical diabetic associations around the world. Our CARA (Computer Assisted Retinal Analysis) platform at Chaparral will help to meet this high value requirement. Higher compliancy with diabetes disease management means: Reduction in blindness, amputations and stage renal disease propensity Increase in quality adjusted life years per patient Significant reduction on care cost with less Emergency Room visit, less days of hospitalization and fewer claims Better Healthcare Effectiveness Data and Information Set (HEDIS) scores and increase in Risk Adjustment Factor (RAF) scores for Chaparral "We are pleased to sign a three year contract with Diagnos, said Dr Prasad, diabetes specialist, President and Medical Director of Chaparral Medical Group. With a retinal scan, we can identify cases of diabetes by having an eye exam 10 years before the complications arise. And if detected early, we can treat it and reduce the incidence of blindness." With the Computer Assisted Retinal Analysis (CARA) Platform, Diagnos is also playing a key role in our Diabetic Champion Program. With it, we can quickly screen our large community of diabetic patients for any signs of diabetic retinopathy. Chaparral is a proud award recipient of "The American Diabetes Association and National Committee for Quality Assurance" Achievement of Recognition for delivery of Quality Diabetes Care. About Chaparral Chaparral Medical Group is a 60 physician multi-specialty group serving in 23 clinics in the communities of Claremont, La Verne, San Dimas, Fontana, Pomona, Rancho Cucamonga, Upland, Chino Hills and Diamond Bar in Southern California. Over 20 primary care physicians serve as the group's clinical core, and work together with their medical and surgical specialists to provide outstanding care to the patient population Southern California. They have been serving the community since 1978 and their unwavering commitment to patient care and physician work satisfaction are what have driven them to become the most trusted and relied-upon group of physicians in their area. About DIAGNOS Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize our Artificial Intelligence technology combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in healthcare. We seek Safe Harbor. 2017 Canjex Publishing Ltd. All rights reserved.
Bullboard Posts